Five-Year Outcomes in Patients With Chronic Total Coronary Occlusion Treated With Drug-Eluting vs Bare-Metal Stents: A Case-Control Study

Comparison of 12-month clinical outcomes in diabetic and nondiabetic patients with chronic total occlusion lesions

“…De Felice et al 23 suggested that DES should be a preferred treatment strategy for CTO because DES reduced TLR by 60% 3 years after the index PCI. In addition, the same investigators showed that the benefits of DES over BMS were maintained up to the 5-year follow-up in patients with CTO 24 . Several other studies also suggested that first-generation DES improved long-term angiographic and clinical outcomes compared with BMS in CTO patients 3 , 13 , 25 .…”

Impact of anemia on long‐term outcomes after percutaneous coronary intervention for chronic total occlusion

“…Cox proportional hazards regression models were applied to assess adjusted risks of the outcome measures in anemic and nonanemic patients and for continuous haemoglobin levels at baseline. Multivariate models were adjusted for prespecified variables known to be associated with worse outcomes in coronary artery disease and PCI (Model 1): Age, gender, diabetes mellitus, dyslipidemia, hypertension, smoking, prior myocardial infarction, prior PCI, prior coronary artery bypass grafting (CABG), multivessel disease, moderate/severe coronary calcification, chronic kidney disease, estimated glomerular filtration rate (eGFR), C‐reactive protein, reduced left ventricular ejection fraction (<40%), number of stents implanted, procedural success, and use of bare metal stents. In order to exclude any potential bias introduced by overfitting, a second model was generated including the following variables only (Model 2): Age, diabetes mellitus, chronic kidney disease, and procedural success .…”

Double Chronic Total Occlusion Recanalisation with Antegrade and Retrograde Techniques and the Use of a Novel Drug-eluting Stent with Biodegradable Polymer

“…16,17 A recent study evaluating DES long-term safety and efficiency in CTO lesions revealed that DES were superior to BMS in reducing major adverse cardiac events (MACEs), target lesion revascularisation (TLR) and target vessel failure (TVF) at five-years. 18 Next generation stents with biodegradable polymer, recently introduced in clinical practice, proved non-inferior to current generation DES with regard to clinical and angiographic endpoints. 19 Notably, in a randomised CTO clinical study, a novel stent with biodegradable polymer -the CORACTO stent -proved superior to a BMS of similar design.…”